[Clinical study of intraperitoneal chemotherapeutic perfusion (IPCP) of mitomycin C (MMC) and intraperitoneal administration of cisplatin].
IPCP was performed in an attempt to control ascites production by malignant tumors, and its inhibitory effect on ascites production was studied. The subjects were 24 patients who underwent surgery at this department between April 1981 and April 1986, consisting of 19 cases of ovarian cancer, 3 cases of cancer of the uterine body, 1 case of retroperitoneal tumor, and 1 case of metastatic ovarian cancer. As the treatment at the time of laparotomy, 30 mg of MMC was dissolved in 300 ml of normal saline and intraperitoneally administered. After holding for 30 minutes, it was discharged by cleaning out the abdominal cavity with 3,000 ml of normal saline. Immediately before closure of the wound, (A): MMC 10 mg, OK-432 100 KE, neocarzinostatin 4,000 units, or (B): (A) + cisplatin 100mg, was intraperitoneally injected, and the wound was closed without washing out this anticancer cocktail after drainage of the abdominal cavity and abdominal wall. Among the present 24 cases, (A) was applied in 17 cases, and (B) in 7 cases. The inhibitory effect on ascites production was 87.5% or 21/24 cases, specifically 88.2% (15/17) in the (A) group and 85.7% (6/7) in the (B) group. There were no particular side effects.
D001201:Ascites / Q000517:prevention & control; D010478:Chemotherapy, Cancer, Regional Perfusion; D002945:Cisplatin / Q000008:administration & dosage* / Q000652:urine; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D007274:Injections, Intraperitoneal; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000097:blood; D010051:Ovarian Neoplasms / Q000188:drug therapy; D013997:Time Factors; D014594:Uterine Neoplasms / Q000188:drug therapy
D008937:Mitomycins; D016685:Mitomycin; D002945:Cisplatin